177 related articles for article (PubMed ID: 26424167)
1. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
Yao K; Goldschmidt R; Turk M; Wesseling J; Stork-Sloots L; de Snoo F; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):81-8. PubMed ID: 26424167
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
4. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
7. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
Gevensleben H; Göhring UJ; Büttner R; Heukamp LC; Kunz G; Dimpfl T; Jackisch C; Ortmann O; Albert US; Bender R; De Snoo F; Krijgsman O; Glas AM; Ergönenc YH; Vogel C; Dykgers A; Langwieder C; Rees M; Anzeneder T
Int J Mol Med; 2010 Dec; 26(6):837-43. PubMed ID: 21042777
[TBL] [Abstract][Full Text] [Related]
8. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
11. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
13. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E; Hendriks MP; van Tilburg M; Barcaru A; Mittempergher L; van Egmond A; Kleijn M; Generali D;
Eur J Cancer; 2022 May; 167():92-102. PubMed ID: 35421703
[TBL] [Abstract][Full Text] [Related]
14. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database.
Vallejos CS; Gómez HL; Cruz WR; Pinto JA; Dyer RR; Velarde R; Suazo JF; Neciosup SP; León M; de la Cruz MA; Vigil CE
Clin Breast Cancer; 2010 Aug; 10(4):294-300. PubMed ID: 20705562
[TBL] [Abstract][Full Text] [Related]
18. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
19. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Viale G; Slaets L; de Snoo FA; Bogaerts J; Russo L; van't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Dell'Orto P; Glas AM; Cardoso F
Breast Cancer Res Treat; 2016 Feb; 155(3):463-9. PubMed ID: 26820652
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
